303-50-4

Usage

Uses

Used in Pharmaceutical Industry:
NORCYCLOBENZAPRINE is used as an intermediate in the synthesis of Cyclobenzaprine N-β-D-Glucuronide for the development of pharmaceutical products. NORCYCLOBENZAPRINE serves as a key component in the production process, enabling the creation of Cyclobenzaprine N-β-D-Glucuronide, which has potential therapeutic applications in the treatment of various medical conditions.

InChI:InChI=1/C19H19N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-13,20H,6,14H2,1H3

Upstream product

• 2222-33-5 dibenzosuberenon 
• 1971-54-6 5-ethyl-5-hydroxy-5H-dibenzo[a,d]cycloheptene 
• 1614-62-6 5-(2'-bromoethylidene)-5H-dibenzo[a,d]cycloheptene 
• 1614-61-5 5-(2-cyanoethylidene)-5H-dibenzo[a,d]cycloheptene 
• 1614-63-7 5-ETHYLIDENE-5H-DIBENZO[a,d]CYCLOHEPTENE 
• 1614-47-7 5-(3-aminopropylidene)-5H-dibenzo[a,d]cycloheptene 
• 74-88-4 methyl iodide 
• 14471-62-6 5-(3-bromo-1-propylidene)-5H-dibenzo[a,d]cycloheptene 
• 74-89-5 methylamine 
• 303-53-7 Cyclobenzaprine 
• 16234-95-0 ethyl N-<3-(5H-dibenzocyclohepten-5-ylidene)propyl>-N-methylcarbamate 

Downstream Products

• 16234-95-0 ethyl N-<3-(5H-dibenzocyclohepten-5-ylidene)propyl>-N-methylcarbamate 

Relevant academic research and scientific papers

Development of tricyclic N-benzyl-4-hydroxybutanamide derivatives as inhibitors of GABA transporters mGAT1-4 with anticonvulsant, antinociceptive, and antidepressant activity

γ-Aminobutyric acid (GABA) neurotransmission has a significant impact on the proper functioning of the central nervous system. Numerous studies have indicated that inhibitors of the GABA transporters mGAT1-4 offer a promising strategy for the treatment of several neurological disorders, including epilepsy, neuropathic pain, and depression. Following our previous results, herein, we report the synthesis, biological evaluation, and structure-activity relationship studies supported by molecular docking and molecular dynamics of a new series of N-benzyl-4-hydroxybutanamide derivatives regarding their inhibitory potency toward mGAT1-4. This study allowed us to identify compound 23a (N-benzyl-4-hydroxybutanamide bearing a dibenzocycloheptatriene moiety), a nonselective GAT inhibitor with a slight preference toward mGAT4 (pIC50 = 5.02 ± 0.11), and compound 24e (4-hydroxy-N-[(4-methylphenyl)-methyl]butanamide bearing a dibenzocycloheptadiene moiety) with relatively high inhibitory activity toward mGAT2 (pIC50 = 5.34 ± 0.09). In a set of in vivo experiments, compound 24e successively showed predominant anticonvulsant activity and antinociception in the formalin model of tonic pain. In contrast, compound 23a showed significant antidepressant-like properties in mice. These results were consistent with the available literature data, which indicates that, apart from seizure control, GABAergic neurotransmission is also involved in the pathophysiology of several psychiatric diseases, however alternative mechanisms underlying this action cannot be excluded. Finally, it is worth noting that the selected compounds showed unimpaired locomotor skills that have been indicated to give reliable results in behavioral assays.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF FIBROMYALGIA PAIN

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of fibromyalgia pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, post herpetic neuralgia, diabetic neuropathy, bipolar depression, stress, cancer pain, and lower back pain.

NOVEL DIARYLALKENE DERIVATIVES AND NOVEL DIARYLALKANE DERIVATIVES

The invention relates to a compound represented by the following general formula (1) or its analogue, which selectively inhibit N-type calcium channels or its analogue, and to a method for treating pain etc. comprising the compound represented by the following general formula (1) or its analogue to a patient in need of such treatment: wherein, A represents CH=CH, etc., a, b, c and d represents CH etc., R1, R2, R3, R4, R5 and R6 represents H etc., V--W represents C=C, etc., n represents 0 to 3, Y1 represents O etc., B represents--(CH2)vCHR21 wherein v is 0 to 3, R21 represents H, a lower alkyl group or the like, etc., G represents--CO--, a covalent bond, etc., m is 0 to 6, R7 and R8 represents H, a lower alkyl group,--COR18a,--COOR20 wherein R18a and R20 each represents a lower alkyl group or the like, etc.

MEDICINAL COMPOSITIONS CONTAINING GABAPENTIN OR PREGABALIN AND N-TYPE CALCIUM CHANNEL ANTAGONIST

The present invention relates to a pharmaceutical composition useful for preventing/treating pain, which comprises combination of gabapentin or pregabalin, or pharmaceutically acceptable salts thereof and N-type calcium channel antagonists or pharmaceutically acceptable salts thereof such as a compound having the following structure.

Tricyclic compounds and method for treating allergic diseases

Tricyclic compounds represented by the following formula: STR1 wherein X represents --CH=CH--, --CH2 O--, or --O--; R1 represents a lower alkyl group, R2 represents a hydrogen atom or a lower alkyl group; and n represents an integer of from 1 to 5, pharmacologically acceptable salts thereof, and a method for preparing the same. The present compounds have anti-allergic and anti-histaminic activities and reduced side effects, and are useful as anti-allergic agents and anti-histaminic agents.

Study on zwitter-ionization of drugs. II. Synthesis and pharmacological activity of some N-[3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)propyl]-N- methylamino- and N-[3-(6H-dibenz[b,e]oxepin-11-ylidene)propyl]-N-methylamino- alkanoic acid derivatives and related compounds

A series of N-[3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)propyl]-N- methylamino- (6a) and N-[3-(6H-dibenz-[b,e]oxepin-11-ylidene)propyl]-N- methylamino-alkanoic acid derivatives (6b) and related compounds (6c-f) were synthesized and examined for pharmacological activities in vitro, i.e., inhibitory effect on monoamine [noradrenaline (NA) and 5-hydroxytryptamine (5-HT)] uptake, inhibitory effect on 5-HT-, histamine-, acetylcholine- and NA-induced contraction, and binding affinity for α2-adrenoceptor and dopamine D2-receptor. In vitro tests indicated that zwitter-ionization was capable of maintaining H1-antihistaminic activity while greatly reducing other pharmacological activities. Further, 6a-f showed much stronger inhibitory effects on compound 48/80-induced lethality in rats than did the corresponding N,N-dimethylamines (2a-f). 3-[N-[3-(6H-Dibenz[b,e]oxepin-11- ylidene)propyl]-N-methylamino]-propionic acid (6b-2), selected as a candidate antiallergic agent of a new type, equally potent in rats and guinea-pigs, exhibited strong inhibitory effects on 48 h homologous passive cutaneous anaphylaxis (PCA) in rats (ED50=0.019 mg/kg, p.o.) and on histamine- induced bronchoconstriction in anesthetized guinea-pigs (ED50=0.0067 mg/kg, p.o.).

5H Dibenzo[a,d]cycloheptene derivatives

Compounds of 5H dibenzo[a,d]-cycloheptenes and 10,11-dihydro-5H-dibenzo[a,d]cycloheptenes which are substituted at their 5-carbon atom with an N-cyanoaminopropyl or an N-cyanoaminopropylidene radical.